Novartis Ag (NVS) Goodwill & Intangibles (2009 - 2026)
Novartis Ag recorded quarterly Goodwill & Intangibles of $1.4 billion in Q1 2026, down 97.45% quarter-over-quarter from $55.0 billion in Q4 2025.
Novartis Ag's Goodwill & Intangibles history runs 14 years deep, the most recent figure standing at $1.4 billion for Q1 2026.
- In Q1 2026, Goodwill & Intangibles changed N/A year-over-year to $1.4 billion; the TTM figure through Mar 2026 stood at $1.4 billion (changed N/A YoY), while the FY2025 annual figure was $55.0 billion, up 6.4% from the prior year.
- Goodwill & Intangibles came in at $1.4 billion for Q1 2026 at Novartis Ag, down from $55.0 billion in the prior quarter.
- In the past five years, Goodwill & Intangibles ranged from a high of $81.7 billion in Q4 2023 to a low of $148.0 million in Q1 2022.
- A 5-year average of $40.3 billion and a median of $53.0 billion in 2024 frame the typical range for Goodwill & Intangibles.
- Across the five-year window, Goodwill & Intangibles soared 206.21% in 2023 and sank 36.72% in 2024, its largest moves.
- Novartis Ag's Goodwill & Intangibles stood at $26.7 billion in 2022, then jumped by 206.21% to $81.7 billion in 2023, then tumbled by 36.72% to $51.7 billion in 2024, then climbed by 6.4% to $55.0 billion in 2025, then tumbled by 97.45% to $1.4 billion in 2026.
- According to Business Quant data, Goodwill & Intangibles over the past three periods registered $1.4 billion, $55.0 billion, and $54.8 billion for Q1 2026, Q4 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.40 Bn |
| Dec 31, 2025 | 54.98 Bn |
| Jun 30, 2025 | 54.79 Bn |
| Dec 31, 2024 | 51.67 Bn |
| Jun 30, 2024 | 53.01 Bn |
| Dec 31, 2023 | 81.66 Bn |
| Jun 30, 2023 | 57.53 Bn |
| Dec 31, 2022 | 26.67 Bn |
| Sep 30, 2022 | 162.00 Mn |
| Jun 30, 2022 | 60.95 Bn |
| Mar 31, 2022 | 148.00 Mn |
| Dec 31, 2021 | 27.19 Bn |
| Sep 30, 2021 | 128.00 Mn |
| Jun 30, 2021 | 63.78 Bn |
| Mar 31, 2021 | 112.00 Mn |
| Dec 31, 2020 | 3.43 Bn |
| Jun 30, 2020 | 66.81 Bn |
| Dec 31, 2019 | 33.95 Bn |
| Jun 30, 2019 | 27.30 Bn |
| Mar 31, 2019 | 505.00 Mn |
| Dec 31, 2018 | 4.99 Bn |
| Sep 30, 2018 | 558.00 Mn |
| Jun 30, 2018 | 74.61 Bn |
| Dec 31, 2017 | 30.49 Bn |
| Dec 31, 2016 | 63.99 Bn |
| Dec 31, 2013 | 358.00 |
| Jun 30, 2010 | 8.00 |
| Mar 31, 2010 | 62.00 |
| Dec 31, 2009 | 22.37 Bn |
| Sep 30, 2009 | 11,812.00 |
| Jun 30, 2009 | 11,395.00 |
| Mar 31, 2009 | 136.00 |